8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate

• UNSPSC Description:

  8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate is an irreversible CYP2A6 inhibitor with IC50s of 8.64 μM and 22.3 μM with pre-incubation and co-incubaition, respectively. 8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate also inhibits MAO-A and MAO-B with IC50s of 60.2 and 38.6 μM, respectively[1].

• Target Antigen:

  Cytochrome P450; Monoamine Oxidase

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/8α-2-methylacryloyloxy-hirsutinolide-13-o-acetate.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(OCC1=C([C@H](C[C@H]2C)OC(C(C)=C)=O)/C(OC1=O)=C\[C@](O[C@]23O)(CC3)C)=O

• Molecular Weight:

  406.43

• References & Citations:

  [1]Prasopthum A, et al. Inhibition effects of Vernonia cinerea active compounds against cytochrome P450 2A6 and human monoamine oxidases, possible targets for reduction of tobacco dependence. Drug Metab Pharmacokinet. 2015 Apr;30(2):174-81.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  67667-71-4